Article
Minimal Disease Activity criteria are used to evaluate PsA disease activity and response to treatment. Given that a patient only has to meet 5 of the 7 criteria, should the individual components be weighted equally?
All News
Dr. Antoni Chan
Tweet
JAK and TYK-2 inhibitors and indications in SpA:
● Tofacitinib ➣ Pan JAKi (AS, PsA)
● Baricitinib ➣ JAK1,2
● Upadacitinib ➣ JAK1 (AxSpA, PsA)
● Deucravacitinib ➣ TYK2 (PsA)
Carol Langford, Year in Review #ACR22 @RheumNow https://t.co/EMLEvptySS
sheila
Tweet
Differences between #uveitis pattern in AS vs. PsA and IBD 👇
This is always asked to our rheum fellows during Kelley's hour 🤓
#ACR22 @RheumNow @rheumarhyme @trishiemd @RheumaRamblings @RheumaRambolMD https://t.co/gWxQ9xdb06
Richard Conway
Tweet
Jorge et al. @AprilJorgeMD Incidence SLE nephritis - 16% onset, 35% 15 years. 44.7% men vs 28.6% women at 10 years. 40% Black, 38% Hispanic, 40% Asian, 23% White. @RheumNow #ACR22 Abstr#0538 https://t.co/Nbx16jZAN7 https://t.co/BEnAtbcIHt
sheila
Tweet
GPA pts can have dacryoadenitis (ddx 👇)
where pt's lateral eye/s can be curved due to swelling.
How to examine? Use thumb to retract eyelid & reveal lacrimal gland underneath, ask pt to look medially
#ACR22 @RheumNow @rheumarhyme @doktora_ging @PhRheumaJr #RheumTwitter https://t.co/pJYMffhYWx
Robert B Chao, MD
Tweet
Deucravacitinib (TYK2 inihibitor) already studied in PsO and PsA, has show efficacy in a phase 2 trial for treatment of SLE.
Improvement in SRI(4), BICLA, LLADS, CLASI-50 and joint count
Abs#1117 @RheumNow #ACR22 https://t.co/XElIuMmud9
sheila
Tweet
🦋Only 15% of pts with localized DLE develop SLE
Risk factors for conversion:
🔸ANA+ at BL
🔸dsDNA+
🔸Gen'd DLE
🔸Cytopenia
🔸Photosensitivity
🔸abn. UA
#ACR22 @RheumNow @rheumarhyme https://t.co/n7cKjC1oaR
Richard Conway
Tweet
Tofighi et al. VTE in SLE nephritis. 10% VTE, 5.2% VTE after SLE nephritis diagnosis. Risks - Black patients, ds-DNA+, SDI, aPL+, SLEDAI. @RheumNow #ACR22 Abstr#0541 https://t.co/G6q0qvirf7 https://t.co/B8STBTMy14
Dr. John Cush
Tweet
Prelude to a Meeting #ACR22
https://t.co/ESjDnNue1H https://t.co/EHt5tgFOn3
Dr. John Cush
Tweet
ACR Best Abstracts - Day 1
The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest).
https://t.co/ndSBqYszlo https://t.co/vOHtLTFux6
Dr. Antoni Chan
Tweet
Across 9 trials of Upadacitinib in RA, PsA and AS, 40%–50% of patients had ≥ 2 CV risk factors, ≥ 65 years 6%–23%. Rates of adjudicated MACE and VTE with UPA were infrequent, consistent with background rates in RA, PsA, and AS Abst 0510 https://t.co/HDkQ6ELnAy #ACR22 @RheumNow https://t.co/SRJYdFFNIQ
Dr. Antoni Chan
Tweet
New concept of sJIA to MAS as a continuum on the spectrum of disease severity. Molecular basis via impact of mTORC1 (mechanistic target of rapamycin complex 1) inhibition in Il1rn-/- mice. Looking forward to the full paper. Huang Z Abs004 https://t.co/3OtIp90PnG #ACR22 @RheumNow https://t.co/PPHQj8bYKu
sheila
Tweet
How can we differentiate statin-assoc autoimmune necrotizing myopathy from toxic statin #myopathy?🔎
Remember this important slide👇
#ACR22 @Rheumnow #acrreview https://t.co/hKMJuGDJWt
sheila
Tweet
Statin therapy may exacerbate underlying neuromuscular disorders.
‼️REMEMBER☝️The only ABSOLUTE contraindication to statins are pts who are HMGCR+
#ACR22 @RheumNow #acrreview https://t.co/A3XGHlrm0X
sheila
Tweet
Interesting study by Dr Ai Li Yeo and colleagues on repetitive anti-dsDNA testing and flare prediction:
🔅Fluctuations (⬆️and ⬇️) in anti-dsDNA >2 fold was assoc'd w/⬆️flares in all groups including persistently + pts.
#ACR22 @RheumNow ABST#327 https://t.co/q0WXnIwV4A
sheila
Tweet
In this study, Dr. Niti Goel shows the under-reporting of race & ethnicity in publications of #psoriaticarthritis clinical trials
🧐Participant diversity is important to consider since different races & ethnicities may respond differently to therapies
#ACR22 @RheumNow ABST0090 https://t.co/BzHpuHYVI5
sheila
Tweet
Post hoc analysis from the SELECT-PsA 1 trial by Dr. @DrLauraCoates and team:
💊Pts on UPA showed greater improvement from BL in RAPID3 vs. ADA in all visits
💊Pts on UPA had better responses in all assessments vs. PBO
Reassuring data. #ACR22 @RheumNow ABST0192 https://t.co/NgeUU5bPPf
Akhil Sood MD
Tweet
Abstr 0383 evaluated the use of previously developed AI algorithm to detect sacroiliitis in a new axSpA cohort. The neural network achieved
-Sensitivity 82%; specificity 81%
-PPV 0.89; NPV 0.70
https://t.co/PDSsiMIQUc
@RheumNow #ACR22 #AI #MachineLearning #AxSpA https://t.co/mXUHUowGhQ
Akhil Sood MD
Tweet
Abstr #0195 examined acceptance of Virtual Reality among pts w/ rheumatic diseases (RD)
- VR naïve & experienced were willing to use VR to manage their RD
- VR experienced pts had ↑ % of perceived usefulness & anticipated enjoyment of VR in dx and mgmt of RD
@RheumNow #ACR22 https://t.co/r7X8Kqp8UN
Eric Dein
Tweet
Abst0338 #ACR22 Transition from CLE to SLE
324 cases of incident cutaneous lupus, mean f/u 8 years
26 pts developed SLE. 5.2% transition by 5 years, <3% risk every 5 yrs from 5-20 years
Risk factors: SCLE, younger age, recent diagnosis
@RheumNow #ACRBest https://t.co/JFcUIkfA9n
